edaravone has been researched along with Acute Ischemic Stroke in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Systematic review and meta-analysis of randomized controlled trials and observational studies comparing edaravone to placebo in adult patients with ischemic stroke." | 9.22 | Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022) |
| " The aim of this meta-analysis was to determine the efficacy and tolerability of edaravone, with or without thrombolytic therapy, in the treatment of patients with acute ischemic stroke." | 9.22 | Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. ( Li, GZ; Nie, LY; Ye, XM; Zhao, K; Zhu, GY, 2022) |
| "Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients." | 9.12 | Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis. ( Chen, LQ; Guan, B; Li, Y; Ming, Q; Yang, DX; Yu, D, 2021) |
| "Early administration of edaravone for acute ischemic stroke patients (AIS) receiving intravenous thrombolysis (IVT) has a potential neuroprotective effect." | 9.12 | Safety and efficacy of edaravone combined with alteplase for patients with acute ischemic stroke: A systematic review and meta-analysis. ( Guo, Y; Hu, R; Lin, Y; Tang, Q; Tang, Y; Wang, X; Yang, J, 2021) |
| "DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment." | 8.31 | A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. ( Cai, C; Cui, Y; Deng, L; He, B; Wang, L; Wang, X; Yang, Y; Zhang, H; Zhou, W; Zhu, B, 2023) |
| " Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved cerebroprotective agent against ischemic stroke and amyotrophic lateral sclerosis, while new formulations that enable improvement of its physicochemical properties and biodistribution are desired." | 8.31 | Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury. ( Fukuta, T; Ikeda-Imafuku, M; Iwao, Y, 2023) |
| "To investigate the efficacy of butylphthalide combined with edaravone in the treatment of acute ischemic stroke and the effect on serum inflammatory factors." | 8.31 | Efficacy of Butylphthalide in Combination with Edaravone in the Treatment of Acute Ischemic Stroke and the Effect on Serum Inflammatory Factors. ( Hong, Z; Li, S; Li, Y; Liu, Y; Wang, J; Xie, S, 2023) |
| "Edaravone dexborneol (EDB) is a traditional prescription that consists of two components, edaravone and (+)-borneol, which have synergistic antioxidant and anti-inflammatory activities in animal models of ischemic stroke." | 8.12 | Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke. ( Ding, L; Hu, R; Liang, J; Liu, X; Song, B; Xu, Y; Zhang, W, 2022) |
| " This study aimed to systematically evaluate the safety and efficacy of the combination of blood-activating herbs with edaravone (EDA) in the treatment of acute ischemic stroke (AIS)." | 8.12 | Efficacy and safety of blood-activating herbs combined with edaravone in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis. ( Jin, H; Su, Z; Sun, W; Yang, Z; Yu, Z; Zhang, S; Zhao, D, 2022) |
| "For investigating an influence on butylphthalide sodium chloride injection combined with edaravone dexborneol on neurological function and serum inflammatory factor levels in sufferers having acute ischemic stroke, 120 sufferers having acute ischemic stroke from September 2020 to September 2021 are chosen for the study subjects." | 8.12 | Effects of Butylphthalide Sodium Chloride Injection Combined with Edaravone Dexborneol on Neurological Function and Serum Inflammatory Factor Levels in Sufferers Having Acute Ischemic Stroke. ( Li, K; Lu, X; Yao, S; Zhang, Q, 2022) |
| "Our previous studies confirm that exogenous reduced nicotinamide adenine dinucleotide phosphate (NADPH) exerts a neuroprotective effect in animal models of ischemic stroke, and its primary mechanism is related to anti-oxidative stress and improved energy metabolism." | 8.12 | NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke. ( Chen, Z; Han, R; Li, M; Mao, GH; Qin, ZH; She, J; Sheng, R; Wang, F; Wang, XX; Wu, JC; Zhang, R, 2022) |
| " Hydroxysafflor Yellow A (HSYA), a popular herbal medicine, is an extract of Carthamus tinctorius and is used to treat ischemic stroke (IS) in China." | 8.12 | Hydroxysafflor Yellow A Alleviates Ischemic Stroke in Rats via HIF-1[Formula: see text], BNIP3, and Notch1-Mediated Inhibition of Autophagy. ( Cui, Q; Fu, Z; Ge, S; Liu, A; Liu, J; Liu, Y; Qin, X; Yu, H; Zhang, G; Zhang, Y, 2022) |
| " However, poor water solubility, low stability, and bioavailability in aqueous media are major EDV drawbacks." | 5.91 | Enhancing the Neuroprotection Potential of Edaravone in Transient Global Ischemia Treatment with Glutathione- (GSH-) Conjugated Poly(methacrylic acid) Nanogel as a Promising Carrier for Targeted Brain Drug Delivery. ( Bijani, S; Danafar, H; Hosseini, MJ; Islambulchilar, Z; Kalantari-Hesari, A; Mozafari, F; Ramazani, A; Rashidzadeh, H; Zare-Molaei, F, 2023) |
| "Salvianolic acid A (SAA) has shown neuroprotective effects against ischemic diseases." | 5.72 | Long-term administration of salvianolic acid A promotes endogenous neurogenesis in ischemic stroke rats through activating Wnt3a/GSK3β/β-catenin signaling pathway. ( Du, GH; Jiang, N; Kong, DW; Kong, LL; Liu, CD; Liu, S; Ma, GD; Pan, ZR; Yang, YJ; Zhang, S; Zhang, W, 2022) |
| "The treatment of acute ischemic stroke (AIS) remains a tough challenge in clinic." | 5.72 | Synthesis and biological evaluation of hybrids from optically active ring-opened 3-N-butylphthalide derivatives and 4-fluro-edaravone as potential anti-acute ischemic stroke agents. ( Huang, Z; Ji, D; Jia, J; Jiao, W; Wang, X; Wu, J; Zhang, Y, 2022) |
| " Although EDV promotes ischemic recovery by inhibiting the generation of ROS, its poor safety and bioavailability limit its clinical applications." | 5.62 | A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke. ( Guo, L; Li, F; Pan, J; Shi, Y; Zhao, L, 2021) |
| " The aim of this meta-analysis was to determine the efficacy and tolerability of edaravone, with or without thrombolytic therapy, in the treatment of patients with acute ischemic stroke." | 5.22 | Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. ( Li, GZ; Nie, LY; Ye, XM; Zhao, K; Zhu, GY, 2022) |
| "Systematic review and meta-analysis of randomized controlled trials and observational studies comparing edaravone to placebo in adult patients with ischemic stroke." | 5.22 | Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022) |
| "Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients." | 5.12 | Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis. ( Chen, LQ; Guan, B; Li, Y; Ming, Q; Yang, DX; Yu, D, 2021) |
| " XNJ is often used along with Edaravone injection (EDA) to treat acute ischemic stroke, they have a synergistic effect in improving patients' blood coagulation and neurological function." | 4.31 | Herb-drug interaction of Xingnaojing injection and Edaravone via pharmacokinetics, mixed inhibition of UGTs, and molecular docking. ( Gao, Y; Li, H; Li, Z; Liang, C; Liu, Z; Peng, P; Qi, D; Yang, Z; Zhang, Q, 2023) |
| "To investigate the efficacy of butylphthalide combined with edaravone in the treatment of acute ischemic stroke and the effect on serum inflammatory factors." | 4.31 | Efficacy of Butylphthalide in Combination with Edaravone in the Treatment of Acute Ischemic Stroke and the Effect on Serum Inflammatory Factors. ( Hong, Z; Li, S; Li, Y; Liu, Y; Wang, J; Xie, S, 2023) |
| " Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved cerebroprotective agent against ischemic stroke and amyotrophic lateral sclerosis, while new formulations that enable improvement of its physicochemical properties and biodistribution are desired." | 4.31 | Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury. ( Fukuta, T; Ikeda-Imafuku, M; Iwao, Y, 2023) |
| "DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment." | 4.31 | A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. ( Cai, C; Cui, Y; Deng, L; He, B; Wang, L; Wang, X; Yang, Y; Zhang, H; Zhou, W; Zhu, B, 2023) |
| " Hydroxysafflor Yellow A (HSYA), a popular herbal medicine, is an extract of Carthamus tinctorius and is used to treat ischemic stroke (IS) in China." | 4.12 | Hydroxysafflor Yellow A Alleviates Ischemic Stroke in Rats via HIF-1[Formula: see text], BNIP3, and Notch1-Mediated Inhibition of Autophagy. ( Cui, Q; Fu, Z; Ge, S; Liu, A; Liu, J; Liu, Y; Qin, X; Yu, H; Zhang, G; Zhang, Y, 2022) |
| "For investigating an influence on butylphthalide sodium chloride injection combined with edaravone dexborneol on neurological function and serum inflammatory factor levels in sufferers having acute ischemic stroke, 120 sufferers having acute ischemic stroke from September 2020 to September 2021 are chosen for the study subjects." | 4.12 | Effects of Butylphthalide Sodium Chloride Injection Combined with Edaravone Dexborneol on Neurological Function and Serum Inflammatory Factor Levels in Sufferers Having Acute Ischemic Stroke. ( Li, K; Lu, X; Yao, S; Zhang, Q, 2022) |
| "Edaravone dexborneol (EDB) is a traditional prescription that consists of two components, edaravone and (+)-borneol, which have synergistic antioxidant and anti-inflammatory activities in animal models of ischemic stroke." | 4.12 | Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke. ( Ding, L; Hu, R; Liang, J; Liu, X; Song, B; Xu, Y; Zhang, W, 2022) |
| "Edaravone has been widely used in the treatment of acute ischemic stroke." | 4.12 | Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats. ( Luo, HY; Parikh, A; Xiong, YX; Ye, QY; Zhao, LQ; Zhou, XF, 2022) |
| "Our previous studies confirm that exogenous reduced nicotinamide adenine dinucleotide phosphate (NADPH) exerts a neuroprotective effect in animal models of ischemic stroke, and its primary mechanism is related to anti-oxidative stress and improved energy metabolism." | 4.12 | NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke. ( Chen, Z; Han, R; Li, M; Mao, GH; Qin, ZH; She, J; Sheng, R; Wang, F; Wang, XX; Wu, JC; Zhang, R, 2022) |
| "DL‑3‑n‑butylphthalide (NBP) and 3‑methyl‑1- phenyl‑2‑pyrazolin‑5‑one (edaravone) are acknowledged neuroprotective agents that protect against ischemic stroke." | 4.02 | Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke. ( Cheng, Y; Guan, Y; Guo, L; Li, P; Liu, Y; Wu, Q, 2021) |
| "Edaravone Dexborneol is a novel neuroprotective agent that comprised edaravone and (+)-borneol, a food additive with an anti-inflammatory effect in animal ischaemic stroke models." | 2.90 | Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial. ( Chen, H; Gao, X; Gao, Z; Wang, A; Wang, Y; Xu, J; Zhao, X; Zhou, J, 2019) |
| "Edaravone is a new antioxidant and hydroxyl radical scavenger." | 2.72 | Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta-analysis of randomized controlled trials. ( Chen, C; Chen, S; Chen, Y; Hong, L; Li, M; Lin, L, 2021) |
| " However, poor water solubility, low stability, and bioavailability in aqueous media are major EDV drawbacks." | 1.91 | Enhancing the Neuroprotection Potential of Edaravone in Transient Global Ischemia Treatment with Glutathione- (GSH-) Conjugated Poly(methacrylic acid) Nanogel as a Promising Carrier for Targeted Brain Drug Delivery. ( Bijani, S; Danafar, H; Hosseini, MJ; Islambulchilar, Z; Kalantari-Hesari, A; Mozafari, F; Ramazani, A; Rashidzadeh, H; Zare-Molaei, F, 2023) |
| "Salvianolic acid A (SAA) has shown neuroprotective effects against ischemic diseases." | 1.72 | Long-term administration of salvianolic acid A promotes endogenous neurogenesis in ischemic stroke rats through activating Wnt3a/GSK3β/β-catenin signaling pathway. ( Du, GH; Jiang, N; Kong, DW; Kong, LL; Liu, CD; Liu, S; Ma, GD; Pan, ZR; Yang, YJ; Zhang, S; Zhang, W, 2022) |
| "The treatment of acute ischemic stroke (AIS) remains a tough challenge in clinic." | 1.72 | Synthesis and biological evaluation of hybrids from optically active ring-opened 3-N-butylphthalide derivatives and 4-fluro-edaravone as potential anti-acute ischemic stroke agents. ( Huang, Z; Ji, D; Jia, J; Jiao, W; Wang, X; Wu, J; Zhang, Y, 2022) |
| "Acute ischemic stroke is a leading cause of disability and death." | 1.72 | Synthesis and biological evaluation of 1,2,4-triazole derivatives as potential Nrf2 activators for the treatment of cerebral ischemic injury. ( Chen, J; Huang, P; Jiang, C; Lao, Y; Shi, J; Su, R; Wang, Y; Zhang, J, 2022) |
| " Although EDV promotes ischemic recovery by inhibiting the generation of ROS, its poor safety and bioavailability limit its clinical applications." | 1.62 | A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke. ( Guo, L; Li, F; Pan, J; Shi, Y; Zhao, L, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 29 (96.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lao, Y | 1 |
| Wang, Y | 5 |
| Chen, J | 2 |
| Huang, P | 1 |
| Su, R | 1 |
| Shi, J | 1 |
| Jiang, C | 1 |
| Zhang, J | 1 |
| Wang, H | 1 |
| Cui, E | 1 |
| Li, J | 2 |
| Ma, X | 1 |
| Jiang, X | 1 |
| Du, S | 1 |
| Qian, S | 1 |
| Du, L | 1 |
| Liu, K | 1 |
| Tao, X | 1 |
| Su, J | 1 |
| Li, F | 2 |
| Mu, F | 1 |
| Zhao, S | 1 |
| Lu, X | 2 |
| Chen, S | 2 |
| Dong, T | 1 |
| Duan, J | 1 |
| Wei, P | 1 |
| Xi, M | 1 |
| Guan, Y | 1 |
| Li, P | 2 |
| Liu, Y | 3 |
| Guo, L | 2 |
| Wu, Q | 1 |
| Cheng, Y | 1 |
| Pan, J | 1 |
| Zhao, L | 1 |
| Shi, Y | 1 |
| Yang, DX | 1 |
| Li, Y | 3 |
| Yu, D | 1 |
| Guan, B | 1 |
| Ming, Q | 1 |
| Chen, LQ | 1 |
| Zhang, S | 3 |
| Kong, DW | 1 |
| Ma, GD | 1 |
| Liu, CD | 1 |
| Yang, YJ | 1 |
| Liu, S | 1 |
| Jiang, N | 1 |
| Pan, ZR | 1 |
| Zhang, W | 3 |
| Kong, LL | 1 |
| Du, GH | 1 |
| Zhang, Y | 2 |
| Cui, Q | 1 |
| Fu, Z | 1 |
| Yu, H | 1 |
| Liu, A | 1 |
| Liu, J | 1 |
| Qin, X | 1 |
| Ge, S | 1 |
| Zhang, G | 1 |
| Li, K | 1 |
| Zhang, Q | 2 |
| Yao, S | 1 |
| Song, MM | 1 |
| Ye, SM | 1 |
| Lu, DP | 1 |
| Zhang, GY | 1 |
| Liu, R | 1 |
| Shen, YX | 1 |
| Zhao, LQ | 1 |
| Parikh, A | 1 |
| Xiong, YX | 1 |
| Ye, QY | 1 |
| Zhou, XF | 1 |
| Luo, HY | 1 |
| Fidalgo, M | 1 |
| Ricardo Pires, J | 1 |
| Viseu, I | 1 |
| Magalhães, P | 1 |
| Gregório, H | 1 |
| Afreixo, V | 1 |
| Gregório, T | 1 |
| Jia, J | 1 |
| Wu, J | 1 |
| Ji, D | 1 |
| Jiao, W | 1 |
| Wang, X | 5 |
| Huang, Z | 1 |
| Huang, Y | 1 |
| Zhang, X | 2 |
| Zhang, C | 1 |
| Xu, W | 1 |
| Li, W | 1 |
| Feng, Z | 1 |
| Zhao, K | 3 |
| Hu, R | 2 |
| Liang, J | 1 |
| Ding, L | 1 |
| Liu, X | 1 |
| Song, B | 1 |
| Xu, Y | 1 |
| Li, GZ | 2 |
| Nie, LY | 2 |
| Ye, XM | 2 |
| Zhu, GY | 2 |
| Su, Z | 2 |
| Yu, Z | 2 |
| Jin, H | 2 |
| Sun, W | 2 |
| Yang, Z | 3 |
| Zhao, D | 2 |
| Qi, D | 1 |
| Li, H | 1 |
| Liang, C | 1 |
| Peng, P | 1 |
| Gao, Y | 1 |
| Li, Z | 1 |
| Liu, Z | 1 |
| Yasutaka, Y | 1 |
| Fujioka, S | 1 |
| Tsuboi, Y | 1 |
| Oyabu, K | 1 |
| Shibaguchi, H | 1 |
| Kamimura, H | 1 |
| Mozafari, F | 1 |
| Rashidzadeh, H | 1 |
| Bijani, S | 1 |
| Zare-Molaei, F | 1 |
| Islambulchilar, Z | 1 |
| Danafar, H | 1 |
| Kalantari-Hesari, A | 1 |
| Ramazani, A | 1 |
| Hosseini, MJ | 1 |
| Hong, Z | 1 |
| Li, S | 2 |
| Xie, S | 1 |
| Wang, J | 2 |
| Fukuta, T | 1 |
| Ikeda-Imafuku, M | 1 |
| Iwao, Y | 1 |
| Zhang, H | 1 |
| Wang, L | 1 |
| Zhu, B | 1 |
| Yang, Y | 1 |
| Cai, C | 1 |
| Deng, L | 1 |
| He, B | 1 |
| Cui, Y | 1 |
| Zhou, W | 1 |
| Su, D | 1 |
| Zhang, R | 2 |
| Ding, Q | 1 |
| Che, F | 1 |
| Wu, W | 1 |
| Tang, B | 1 |
| Xu, J | 3 |
| Wang, A | 2 |
| Gao, Z | 2 |
| Gao, X | 1 |
| Chen, H | 2 |
| Zhou, J | 1 |
| Zhao, X | 2 |
| Meng, X | 1 |
| Yalkun, G | 1 |
| Xu, A | 1 |
| Ji, Y | 1 |
| Geng, D | 1 |
| Zhu, R | 1 |
| Liu, B | 1 |
| Dong, A | 1 |
| Mu, H | 1 |
| Lu, Z | 1 |
| Zheng, H | 1 |
| Chen, X | 1 |
| Chen, C | 1 |
| Li, M | 2 |
| Lin, L | 1 |
| Chen, Y | 1 |
| Hong, L | 1 |
| Guo, Y | 1 |
| Lin, Y | 1 |
| Tang, Y | 1 |
| Tang, Q | 1 |
| Yang, J | 1 |
| Vdovychenko, YP | 1 |
| Loskutov, OA | 1 |
| Halushko, OA | 1 |
| Trishchynska, MA | 1 |
| Dziuba, DO | 1 |
| Povietkina, TM | 1 |
| Vitiuk, AD | 1 |
| Wang, XX | 1 |
| Wang, F | 1 |
| Mao, GH | 1 |
| Wu, JC | 1 |
| Han, R | 1 |
| She, J | 1 |
| Sheng, R | 1 |
| Chen, Z | 1 |
| Qin, ZH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Multi-dose, Parallel, and Controlled Phase II Trial[NCT01929096] | Phase 2 | 400 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Treatment of Acute Ischemic STroke With Edaravone Dexborneol Ⅱ (TASTE-2)[NCT05249920] | Phase 3 | 1,362 participants (Actual) | Interventional | 2022-03-18 | Completed | ||
| Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled PhaseⅢTrial[NCT02430350] | Phase 3 | 1,200 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke-A Multicenter, Randomized, Double-blind, Placebo-controlled, Trial[NCT05885919] | Phase 3 | 212 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for edaravone and Acute Ischemic Stroke
| Article | Year |
|---|---|
Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis.
Topics: Brain Ischemia; Edaravone; Humans; Ischemic Stroke; Stroke; Tissue Kallikreins; Treatment Outcome | 2021 |
Edaravone for acute ischemic stroke - Systematic review with meta-analysis.
Topics: Adult; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Intracranial Hemorrha | 2022 |
Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis.
Topics: Edaravone; Hemorrhage; Humans; Ischemic Stroke; Neuroprotective Agents; Stroke | 2022 |
Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis.
Topics: Edaravone; Hemorrhage; Humans; Ischemic Stroke; Neuroprotective Agents; Stroke | 2022 |
Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis.
Topics: Edaravone; Hemorrhage; Humans; Ischemic Stroke; Neuroprotective Agents; Stroke | 2022 |
Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis.
Topics: Edaravone; Hemorrhage; Humans; Ischemic Stroke; Neuroprotective Agents; Stroke | 2022 |
Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta-analysis of randomized controlled trials.
Topics: Age Factors; Edaravone; Humans; Ischemic Stroke; Neuroprotective Agents; Randomized Controlled Trial | 2021 |
Safety and efficacy of edaravone combined with alteplase for patients with acute ischemic stroke: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Combined Modality Therapy; Drug Combinations; Edaravone; Humans; Ischem | 2021 |
2 trials available for edaravone and Acute Ischemic Stroke
23 other studies available for edaravone and Acute Ischemic Stroke
| Article | Year |
|---|---|
Synthesis and biological evaluation of 1,2,4-triazole derivatives as potential Nrf2 activators for the treatment of cerebral ischemic injury.
Topics: Animals; Heme Oxygenase-1; Ischemic Stroke; Kelch-Like ECH-Associated Protein 1; Neuroprotective Age | 2022 |
Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cyclooxygenase 2; Disease Models, Animal; Indazol | 2022 |
Network pharmacology and molecular docking reveal the effective substances and active mechanisms of Dalbergia Odoriferain protecting against ischemic stroke.
Topics: Animals; Cell Survival; Cerebral Infarction; Dalbergia; Drugs, Chinese Herbal; Edaravone; Gene Expre | 2021 |
Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke.
Topics: Animals; Apoptosis Regulatory Proteins; Benzofurans; Brain Ischemia; Disease Models, Animal; Drug Th | 2021 |
A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke.
Topics: Brain; Brain Ischemia; Edaravone; Exosomes; Free Radical Scavengers; Humans; Ischemic Stroke; Stroke | 2021 |
Long-term administration of salvianolic acid A promotes endogenous neurogenesis in ischemic stroke rats through activating Wnt3a/GSK3β/β-catenin signaling pathway.
Topics: Animals; beta Catenin; Caffeic Acids; Edaravone; Glycogen Synthase Kinase 3 beta; Ischemic Stroke; L | 2022 |
Hydroxysafflor Yellow A Alleviates Ischemic Stroke in Rats via HIF-1[Formula: see text], BNIP3, and Notch1-Mediated Inhibition of Autophagy.
Topics: Animals; Autophagy; Brain Ischemia; Chalcone; Edaravone; Hypoxia-Inducible Factor 1; Ischemic Stroke | 2022 |
Effects of Butylphthalide Sodium Chloride Injection Combined with Edaravone Dexborneol on Neurological Function and Serum Inflammatory Factor Levels in Sufferers Having Acute Ischemic Stroke.
Topics: Benzofurans; Edaravone; Humans; Interleukin-6; Ischemic Stroke; Quality of Life; Sodium Chloride; St | 2022 |
Targeted delivery of edaravone by liposomes for the treatment of ischemic stroke.
Topics: Animals; Brain; Edaravone; Ischemic Stroke; Liposomes; Rats; Stroke; Tissue Distribution | 2022 |
Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats.
Topics: Animals; Antipyrine; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Ischemi | 2022 |
Synthesis and biological evaluation of hybrids from optically active ring-opened 3-N-butylphthalide derivatives and 4-fluro-edaravone as potential anti-acute ischemic stroke agents.
Topics: Animals; Benzofurans; Edaravone; Ischemic Stroke; Neuroprotective Agents; Rats; Stroke | 2022 |
Edaravone Dexborneol Downregulates Neutrophil Extracellular Trap Expression and Ameliorates Blood-Brain Barrier Permeability in Acute Ischemic Stroke.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Deoxyribonuclease I; Edaravone; Extracellular Traps; H | 2022 |
Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke.
Topics: Animals; Edaravone; Infarction, Middle Cerebral Artery; Inflammasomes; Ischemic Stroke; Mice; Microg | 2022 |
Efficacy and safety of blood-activating herbs combined with edaravone in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis.
Topics: China; Edaravone; Humans; Ischemic Stroke; Meta-Analysis as Topic; Systematic Reviews as Topic | 2022 |
Efficacy and safety of blood-activating herbs combined with edaravone in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis.
Topics: China; Edaravone; Humans; Ischemic Stroke; Meta-Analysis as Topic; Systematic Reviews as Topic | 2022 |
Efficacy and safety of blood-activating herbs combined with edaravone in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis.
Topics: China; Edaravone; Humans; Ischemic Stroke; Meta-Analysis as Topic; Systematic Reviews as Topic | 2022 |
Efficacy and safety of blood-activating herbs combined with edaravone in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis.
Topics: China; Edaravone; Humans; Ischemic Stroke; Meta-Analysis as Topic; Systematic Reviews as Topic | 2022 |
Herb-drug interaction of Xingnaojing injection and Edaravone via pharmacokinetics, mixed inhibition of UGTs, and molecular docking.
Topics: Animals; Chromatography, Liquid; Edaravone; Glucuronosyltransferase; Herb-Drug Interactions; Ischemi | 2023 |
Liver toxicity of intravenous heparin treatment in patients with acute ischemic stroke.
Topics: Anticoagulants; Cerebral Infarction; Edaravone; Enoxaparin; Heparin; Humans; Ischemic Stroke; Liver; | 2023 |
Enhancing the Neuroprotection Potential of Edaravone in Transient Global Ischemia Treatment with Glutathione- (GSH-) Conjugated Poly(methacrylic acid) Nanogel as a Promising Carrier for Targeted Brain Drug Delivery.
Topics: Acute Disease; Animals; Antioxidants; Brain; Edaravone; Glutathione; Ischemia; Ischemic Stroke; Nano | 2023 |
Efficacy of Butylphthalide in Combination with Edaravone in the Treatment of Acute Ischemic Stroke and the Effect on Serum Inflammatory Factors.
Topics: Benzofurans; Edaravone; Humans; Inflammation; Interleukin-6; Ischemic Stroke; Stroke | 2023 |
Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury.
Topics: Animals; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Ionic Liquids; Ischemic Str | 2023 |
A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats.
Topics: Animals; Brain Ischemia; Edaravone; Infarction, Middle Cerebral Artery; Inflammation; Ischemic Strok | 2023 |
A new multi-parameter imaging platform for in vivo drug efficacy evaluation of ischemic stroke.
Topics: Edaravone; Formaldehyde; Humans; Ischemic Stroke; Malondialdehyde; Optical Imaging | 2024 |
ACUTE ISCHEMIC STROKE IN WOMEN: EFFICACY OF THE FREE RADICAL SCAVENGER EDARAVONE.
Topics: Brain Ischemia; Edaravone; Female; Free Radical Scavengers; Humans; Ischemic Stroke; Prospective Stu | 2021 |
NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Edaravone; Infarction, Middle Cer | 2022 |